If work performed for you at the San Diego CFAR Biostatistics and Modeling Core results in publication, please acknowledge us with the following statement so that we may continue to bring you excellent service:

This work was performed with the support of the Biostatistics and Modeling Core of the San Diego Center for AIDS Research (AI036214).


Please e-mail a PDF of your publication to

2017 Publications

  1. Browne SH, Diaz-Perez JA, Preziosi M, King CC, Jones GA, Jain S, Sun X, Reid EG, VandenBerg S, Wang HY. mTOR activity in AIDS-related diffuse large B-cell lymphoma. PLoS One. 2017;12(2):e0170771. PMID: 28192480. PMCID: 5305194. +
  1. Gaines TL, Werb D, Arredondo J, Alaniz VM, Vilalta C, Beletsky L. The spatial-temporal pattern of policing following a drug policy reform: Triangulating self-reported arrests with official crime statistics. Subst Use Misuse. 2017;52(2):214-222. PMID: 27767367. PMCID: 5378066.
  1. Gountas I, Sypsa V, Anagnostou O, Martin NK, Vickerman P, Kafetzopoulos E, Hatzakis A. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: Is elimination possible in a high prevalence setting? Addiction. 2017:Epub ahead of print. PMID: 28107585.
  1. Hickman M, Martin NK, Huxtable R. Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs. Addiction. 2017;112(2):201-203. PMID: 27514647. PMCID: 5233591.
  1. Karris MY, Jain S, Day TR, Perez-Santiago J, Goicoechea M, Dube MP, Sun X, Spina C, Daar ES, Haubrich RH, Morris S, California Collaborative Treatment Group 589 Study Team. HIV viral kinetics and T cell dynamics in antiretroviral naive persons starting an integrase strand transfer inhibitor and protease inhibitor regimen. HIV Clin Trials. 2017;18(2):67-74. PMID: 28134057. +
  1. MacGregor L, Martin NK, Mukandavire C, Hickson F, Weatherburn P, Hickman M, Vickerman P. Behavioural not biological factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact.  Int J Epidemiol 2017 (in press)
  1. Martin NK, Vickerman P, Hickman M. How to eliminate HCV infection by antiviral treatment. J Hepatol. 2017;s0168-8278(17):30142-3. PMID: 28323120.
  1. Martin NK, Skaathun B, Vickerman P, Stuart D. Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex with Men and People Who Inject Drugs. AIDS Rev 2017 (in press).
  1. Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, Munro A, Dunleavy K, Peters E, Bramley P, Hayes PC, Goldberg DJ, Vickerman P. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction 2017 (in press).


2016 Publications

  1. Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, Taxman FS, El-Bassel N, Martin NK, Booth R, Stover H, Dolan K, Vickerman P. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016;388(10050):1228-1248. PMID: 27427455. PMCID: 5087988.
  1. Aspinall EJ, Mitchell W, Schofield J, Cairns A, Lamond S, Bramley P, Peters SE, Valerio H, Tomnay J, Goldberg DJ, Mills PR, Barclay ST, Fraser A, Dillon JF, Martin NK, Hickman M, Hutchinson SJ. A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepat. 2016:[Epub ahead of print]. PMID: 27509844. PMCID: PMC Journal - in process.
  1. Borquez A, Cori A, Pufall EL, Kasule J, Slaymaker E, Price A, Elmes J, Zaba B, Crampin AC, Kagaayi J, Lutalo T, Urassa M, Gregson S, Hallett TB. The incidence patterns model to estimate the distribution of new HIV infections in Sub-Saharan Africa: Development and validation of a mathematical model. PLoS Med. 2016;13(9):e1002121. PMID: 27622516. PMCID: 5021265.
  1. Caceres CF, Borquez A, Klausner JD, Baggaley R, Beyrer C. Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy. J Int AIDS Soc. 2016;19(7(Suppl 6)):21108. PMID: 27760685. PMCID: 5071779.
  1. Chaillon A, Hoenigl M, Mehta SR, Weibel N, Little SJ, Smith DM. A practical online tool to estimate antiretroviral coverage for HIV infected and susceptible populations needed to reduce local HIV epidemics. Sci Rep. 2016;6:28707. PMID: 27337983. PMCID: 4919622.
  1. Fraser H, Mukandavire C, Martin NK, Hickman M, Cohen MS, Miller WC, Vickerman P. HIV treatment as prevention among people who inject drugs: a re-evaluation of the evidence. Int J Epidemiol. 2016:Epub ahead of print. PMID: 27524816.
  1. Harris RJ, Martin NK, Rand E, Mandal S, Mutimer D, Vickerman P, Ramsay ME, De Angelis D, Hickman M, Harris HE. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat. 2016;23(8):631-643. PMID: 27025238. PMCID: 4982023.
  1. Innes S, Abdullah KL, Haubrich R, Cotton MF, Browne SH. High prevalence of dyslipidemia and insulin resistance in HIV-infected prepubertal African children on antiretroviral therapy. Pediatr Infect Dis J. 2016;35(1):e1-7. PMID: 26421804. PMCID: 4707556. +
  1. Karris MY, Jain S, Bowman VQ, Rieg G, Goicoechea M, Dube MP, Kerkar S, Kemper C, Diamond C, Sun X, Daar ES, Haubrich RH, Morris S, California Collaborative Treatment Group 589 Study Team. Nucleoside-sparing regimens with raltegravir and a boosted protease inhibitor: an unsettled ussue. J Acquir Immune Defic Syndr. 2016;72(2):e48-50. PMID: 26977746. PMCID: 4867124. +
  1. Martin NK, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, Martin TC, Delpech V, Ruf M, Price H, Azad Y, Thomson EC, Vickerman P. Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights. Clin Infect Dis. 2016;62(9):1072-1080. PMID: 26908813. PMCID: 4826456.
  1. Martin NK, Vickerman P, Brew IF, Williamson J, Miners A, Irving WL, Saksena S, Hutchinson SJ, Mandal S, O'Moore E, Hickman M. Is increased hepatitis C virus case-finding combined with current or 8-12 week DAA therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology. 2016;63(6):1796-1808. PMID: 26864802. PMCID: 4920048.
  1. Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, Foster GR, Hutchinson SJ, Goldberg DJ, Martin TC, Ramsay M, Consortium S-H, Hickman M. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol. 2016;65(1):17-25. PMID: 26867489. PMCID: 4914770.
  1. Martin NK, Vickerman P, Hickman M. Reply. Hepatology. 2016;64(5):1822-1823. PMID: 27112633. PMCID: Not peer reviewed.
  1. Martin NK, Vickerman P, Hickman M, Patterson TL, Rand E, Abramovitz D, Strathdee SA. Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV prevention. Addiction. 2016;111(9):1512-1515. PMID: 27075692. PMCID: 4983200.
  1. Milam J, Morris S, Jain S, Sun X, Dube MP, Daar ES, Jimenez G, Haubrich R, and the CCTG 592 Team. Randomized controlled trial of an internet application to reduce HIV transmission behavior among HIV infected men who have sex with men. AIDS Behav. 2016;20(6):1173-1181. PMID: 26487300. PMCID: 4838553. +
  1. Seifert M, Ajbani K, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, Garfein RS, Catanzaro A, Rodwell TC. A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20(5):631-637. PMID: 27084817. PMCID: 4852300. +
  1. Seifert M, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, Garfein RS, Catanzaro A, Rodwell TC. MTBDRplus and MTBDRsl assays: Absence of wild-type probe hybridization and implications for detection of drug-resistant tuberculosis. J Clin Microbiol. 2016;54(4):912-918. PMID: 26763971. PMCID: 4809938. +
  1. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJ, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed Zaki M, Cooke GS. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081-1088. PMID: 27394647. PMCID: 5100695
  1. Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P. The potential impact of a hepatitis C vaccine for people who inject drugs: Is a vaccine needed in the age of direct-acting antivirals? PLoS One. 2016;11(5):e0156213. PMID: 27224423. PMCID: 4880220.

At a Glance